

ORIGINAL ARTICLE

Clinical factors associated with C-reactive protein in chronic spinal cord injury

RL Goldstein¹, P Walia¹, M Teylan¹, AA Lazzari², CG Tun³, JE Hart^{4,5,6} and E Garshick^{5,6,7}

Study design: Cross-sectional study.

Objectives: Determine clinical factors associated with plasma C-reactive protein (CRP) in persons with chronic spinal cord injury (SCI).

Setting: Veterans Affairs Medical Center in Boston, MA, USA.

Methods: Participants provided a blood sample, completed a respiratory health questionnaire and underwent dual X-ray absorptiometry (DXA) to assess total and regional body fat. Linear regression models were used to assess cross-sectional associations with plasma CRP.

Results: In multivariable models, factors associated with a higher CRP included a greater BMI, urinary catheter use, a respiratory illness in the past week and non-white race. Mean CRP also increased with decreasing mobility (motorized wheelchair > hand-propelled wheelchair > walk with an assistive device > walk independently). Results were similar when adjusting for percentage android, gynoid, trunk or total fat mass in place of BMI. Level and completeness of SCI was not associated with CRP in multivariable models.

Conclusions: Clinical characteristics common in chronic SCI are associated with plasma CRP. These factors are more important than the level and completeness of SCI and some are potentially modifiable.

Spinal Cord (2017) **55**, 1088–1095; doi:10.1038/sc.2017.81; published online 1 August 2017

INTRODUCTION

Chronic spinal cord injury (SCI) is characterized by clinical factors that promote systemic inflammation, including reduced mobility,^{1–5} accumulation of central fat^{6–8} and recurrent infections.^{9,10} The linkage between systemic inflammation as assessed by C-reactive protein (CRP) and the development of atherosclerosis and coronary heart disease is well established.¹¹ As individuals with SCI age, they are at increased risk for developing cardiovascular disease,¹² which has become a major cause of mortality in the population with SCI.^{13–18}

Although elevated CRP levels have previously been described in chronic SCI,^{19–22} to date, there has been a limited description of clinical factors that contribute. Slowly healing pressure ulcers in 34 men with SCI,⁹ urinary tract infections in 37 men,¹⁰ tetraplegia compared to paraplegia in 69 men and women²³ and greater fat mass and body mass index (BMI) in 77 men and women have been associated with elevated CRP levels.²⁴ In a previous report in 63 individuals, we found that mobility mode, a greater BMI, heart disease and a pressure ulcer reported in the past year were each associated with higher circulating CRP.²⁵ A limitation of these previous reports, however, is a reduced ability to assess multiple covariates due to small sample sizes. The objective of this report is to assess the robustness of our previous findings in a new chronic SCI cohort with more than five times as many participants, as well as to assess the impact of additional

factors, including fat mass assessed by dual x-ray absorptiometry (DXA) on levels of CRP.

MATERIALS AND METHODS

Subjects

Between August 2009 and April 2015 we recruited 360 individuals into a study of respiratory health among individuals with chronic SCI. Participants were recruited from patients receiving care at VA Boston, from the greater Boston area through advertisement, and by direct mail to persons who had received care at Spaulding Rehabilitation Hospital, Boston University Medical Center, were members of the National Spinal Cord Injury Association, or were subscribers to *New Mobility Magazine*. Individuals were eligible if they were 22 years of age or older, were 1 or more years post injury, had no other neuromuscular disease, did not have a tracheostomy and were able to breathe without chronic ventilatory support. Participants were eligible regardless of etiology of SCI, and testing was scheduled when subjects were free of acute illness. The Institutional Review Board at VA Boston Healthcare System approved the protocol, and informed consent was obtained. We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during the course of this research.

Neurological exam, stature and weight

SCI level and severity was assessed by exam and medical record review.²⁶ Motor incomplete SCI included AIS C (most key muscles below the neurological level

¹Research and Development Service, VA Boston Healthcare System, Boston, MA, USA; ²Division of Primary Care and Rheumatology Section, VA Boston Healthcare System, Boston, MA, USA; ³Department of Physical Medicine and Rehabilitation, VA Boston Healthcare System, Boston, MA, USA; ⁴Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA; ⁵Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; ⁶Harvard Medical School, Boston, MA, USA and ⁷Pulmonary, Allergy, Sleep, and Critical Care Medicine Section, Medical Service, VA Boston Healthcare System, Boston, MA, USA

Correspondence: Dr E Garshick, Pulmonary, Allergy, Sleep, and Critical Care Medicine Section, Medical Service, VA Boston Healthcare System, 1400 VFW Parkway, West Roxbury, MA 02132, USA.

E-mail: Eric.Garshick@va.gov

Received 30 March 2017; revised 5 June 2017; accepted 6 June 2017; published online 1 August 2017

Table 1 Locomotive mode and participant characteristics (N = 338)

| Characteristics | Motorized wheelchair (n = 64) | Hand-propelled wheelchair (n = 150) | Walks with an aid (n = 57) | Walks without assistance (n = 67) | Total (n = 338) |
|---|-------------------------------------|---|----------------------------------|---|--------------------|
| CRP (mg l ⁻¹) (median, 25 percentile, 75 percentile) | 4.57 (2.71, 11.47) | 2.55 (1.15, 7.18) | 1.70 (0.85, 6.67) | 1.42 (0.51, 2.91) | 2.54 (1.04, 7.09) |
| Age (years) (mean, s.d.) | 53.3 ± 14.7 | 49.0 ± 13.3 | 62.7 ± 13.1 | 58.9 ± 12.6 | 54.1 ± 14.4 |
| Injury Duration (years) (mean, SD) | 17.2 ± 15.2 | 17.7 ± 12.0 | 18.7 ± 15.3 | 15.5 ± 12.3 | 17.3 ± 13.3 |
| BMI (kg m ⁻²) (mean, s.d.) | 27.5 ± 6.3 | 26.2 ± 6.1 | 29.8 ± 5.4 | 27.5 ± 6.0 | 27.3 ± 6.1 |
| <i>Percent fat (mean, s.d.)</i> | | | | | |
| Android region, % fat | 44.6 ± 11.0 | 42.6 ± 13.0 | 43.5 ± 11.0 | 38.4 ± 13.7 | 42.3 ± 12.6 |
| Gynoid region, % fat | 44.6 ± 8.8 | 41.8 ± 9.5 | 37.8 ± 9.3 | 33.8 ± 8.7 | 40.1 ± 9.9 |
| Trunk region, % fat | 42.6 ± 9.4 | 39.9 ± 11.4 | 39.9 ± 9.6 | 35.1 ± 11.7 | 39.4 ± 11.0 |
| Total body, % fat | 40.5 ± 7.5 | 36.8 ± 9.0 | 35.9 ± 8.1 | 31.6 ± 8.6 | 36.3 ± 8.9 |
| | (n, %) | (n, %) | (n, %) | (n, %) | (n, %) |
| <i>Race</i> | | | | | |
| White | 56 (87.5) | 132 (88.0) | 47 (82.5) | 57 (85.1) | 292 (86.4) |
| Black | 7 (10.9) | 9 (6.0) | 8 (14.0) | 5 (7.5) | 29 (8.6) |
| Other | 1 (1.6) | 9 (6.0) | 2 (3.5) | 5 (7.5) | 17 (5.0) |
| <i>Sex</i> | | | | | |
| Female | 17 (26.6) | 24 (16.0) | 8 (14.0) | 11 (16.4) | 60 (17.8) |
| Male | 47 (73.4) | 126 (84.0) | 49 (86.0) | 56 (83.6) | 278 (82.3) |
| <i>SCI classification</i> | | | | | |
| Motor complete cervical and AIS C | 43 (67.2) | 36 (24.0) | 1 (1.8) | 0 (0.0) | 80 (23.7) |
| Motor complete high thoracic ^a and AIS C | 8 (12.5) | 38 (25.3) | 0 (0.0) | 0 (0.0) | 46 (13.6) |
| Other motor complete and AIS C | 4 (6.3) | 58 (38.7) | 5 (8.8) | 1 (1.5) | 68 (20.1) |
| All AIS D | 9 (14.1) | 18 (12.0) | 51 (89.5) | 66 (98.5) | 144 (42.6) |
| <i>BMI (kg m⁻²)</i> | | | | | |
| Normal (<25) | 20 (31.3) | 68 (45.3) | 13 (22.8) | 23 (34.3) | 124 (36.7) |
| Overweight (25 ≤ BMI < 30) | 21 (32.8) | 47 (31.3) | 20 (35.1) | 25 (37.3) | 113 (33.4) |
| Obese (≥30) | 23 (35.9) | 35 (23.3) | 24 (42.1) | 19 (28.4) | 101 (29.9) |
| <i>Skin ulcers</i> | | | | | |
| Now | 15 (23.4) | 21 (14.0) | 2 (3.5) | 0 (0.0) | 38 (11.2) |
| In the past year | 31 (48.4) | 49 (32.7) | 3 (5.3) | 2 (3.0) | 85 (25.2) |
| In the past 3 years | 36 (56.3) | 64 (42.7) | 6 (10.5) | 2 (3.0) | 108 (32.0) |
| <i>Urinary tract infections</i> | | | | | |
| Now | 10 (15.6) | 13 (8.7) | 1 (1.8) | 1 (1.5) | 25 (7.4) |
| In the past year | 45 (70.3) | 100 (66.7) | 12 (21.1) | 6 (9.0) | 163 (48.2) |
| In the past 3 years | 56 (87.5) | 105 (70.0) | 20 (35.1) | 18 (26.9) | 199 (58.9) |
| <i>Use of urinary catheter</i> | | | | | |
| No catheter use | 11 (17.2) | 31 (20.7) | 44 (77.2) | 61 (91.0) | 147 (43.5) |
| Catheter use | 53 (82.8) | 119 (79.3) | 13 (22.8) | 6 (9.0) | 191 (56.5) |
| Periodic catheterization | 15 (23.4) | 79 (52.7) | 10 (17.5) | 5 (7.5) | 109 (32.3) |
| Chronic catheter | 33 (51.6) | 17 (11.3) | 1 (1.8) | 1 (1.5) | 52 (15.4) |
| Condom catheter | 5 (7.8) | 23 (15.3) | 2 (3.5) | 0 (0.0) | 30 (8.9) |
| Statin use | 14 (21.9) | 39 (26.0) | 24 (42.1) | 31 (46.3) | 108 (32.0) |
| Heart disease | 5 (7.8) | 9 (6.0) | 21 (36.8) | 4 (6.0) | 39 (11.5) |
| Hypertension | 14 (21.9) | 43 (28.7) | 36 (63.2) | 31 (46.3) | 124 (36.7) |
| Diabetes | 6 (9.4) | 17 (11.3) | 15 (26.3) | 12 (17.9) | 50 (14.8) |
| Regular dental care | 40 (62.5) | 98 (65.3) | 32 (56.1) | 35 (52.2) | 205 (60.7) |
| Chest illness in the past year | 11 (17.2) | 15 (10.0) | 6 (10.5) | 9 (13.4) | 41 (12.1) |
| Chest illness in past 3 years (n = 337) | 22 (34.4) | 32 (21.3) | 12 (21.4) | 16 (23.9) | 82 (24.3) |

Table 1 (Continued)

| Characteristics | Motorized wheelchair (n = 64) | Hand-propelled wheelchair (n = 150) | Walks with an aid (n = 57) | Walks without assistance (n = 67) | Total (n = 338) |
|---|-------------------------------------|---|----------------------------------|---|--------------------|
| <i>Respiratory illness in past 1 week (n = 336)</i> | | | | | |
| No respiratory illness | 63 (100.0) | 137 (92.0) | 51 (89.5) | 59 (88.1) | 310 (92.3) |
| Mild cold ^b or other respiratory illness | 0 (0.0) | 12 (8.0) | 6 (10.5) | 8 (11.9) | 26 (7.7) |
| COPD | 5 (7.8) | 10 (6.7) | 8 (14.0) | 11 (16.4) | 34 (10.1) |
| Asthma | 10 (15.6) | 14 (9.3) | 10 (17.5) | 11 (16.4) | 45 (13.3) |
| COPD or asthma | 14 (21.9) | 22 (14.7) | 16 (28.1) | 19 (28.4) | 71 (21.0) |
| <i>Cigarette Use</i> | | | | | |
| Current | 11 (17.2) | 22 (14.7) | 11 (19.3) | 15 (22.4) | 59 (17.5) |
| Former | 24 (37.5) | 52 (34.7) | 31 (54.4) | 34 (50.8) | 141 (41.7) |
| Pack years (n=200 ever smokers) (median, 25 percentile, 75 percentile) | 20 (9.0, 38.0) | 12.8 (3.5, 26.0) | 25 (11.0, 39.0) | 26.5 (9.2, 45.0) | 18.3 (5.1, 38.0) |
| Never | 29 (45.3) | 76 (50.7) | 15 (26.3) | 18 (26.9) | 138 (40.8) |

Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease.
^aHigh thoracic = T1–T6.
^bMild cold, n = 16 (4.8%).

grade <3/5) or AIS D (most muscles below the neurological level grade ≥3/5). For analysis, participants were further grouped into cervical motor complete (AIS A or B) and cervical AIS C, high thoracic (T1–T6) complete (AIS A or B) and AIS C, others with T7 or below motor complete (AIS A or B) or AIS C, and all others (AIS D's). Height was obtained by measuring the body length from top of the head to the heel of the subject in a supine position. Supine length was measured in 307 (91%) and obtained by self-report in 31 (9%) persons when contractures precluded accurate measurement (see statistical analysis). If required, wheelchairs were weighed with and without the participant, and wheelchair weight subtracted. In 5 persons, self-report of weight was used. BMI (kg m^{-2}) was calculated from height and weight.

DXA for percentage body fat

A 5th generation GE Healthcare iDXA scanner was used to assess percentage total body, percentage trunk, percentage android and percentage gynoid fat using GE Lunar software analyzed by a certified clinical densitometrist (AAL). Daily quality assurance was performed utilizing a phantom. The trunk region was defined by cuts passing through the shoulders and extended inferiorly as close to the body as possible through the femoral necks. The lower boundary of the android region was a horizontal cut at the level of the iliac crests and the upper boundary extended upward to 20% of the distance between the pelvis and shoulders. For the gynoid region, the upper boundary was the iliac crests and the lower boundary included the pelvis and extended downward 1.5 times the height of the android region.

Health questionnaire

A questionnaire based on American Thoracic Society Division of Lung Diseases ATS DLD-78²⁷ was used to obtain a history of cigarette smoking, comorbid medical diseases and statin use. Hypertension, diabetes and asthma were defined based on report of a diagnosis by a doctor, and chronic obstructive pulmonary disease (COPD) was defined as either doctor-diagnosed emphysema or chronic bronchitis. Heart disease was defined as treatment for 'heart trouble' reported in the 10 years prior to study entry. Participants were asked to report whether a chest illness kept them off work, indoors at home or in bed in the previous one and three years, whether they had had a respiratory illness in the past week, whether they currently had a urinary tract infection (UTI) or a skin ulcer, or whether they had experienced either in the past 1 and 3 years, how they usually passed urine, and whether they received regular dental care. Usual mobility mode (>50% of the time) was ascertained in four categories: motorized wheelchair use, hand-propelled wheelchair use, walk with aid such as crutch or cane, or walk without assistance.

Biochemical analyses

Plasma samples were drawn into an EDTA tube and immediately delivered to a core blood research laboratory. The samples were centrifuged for 15 min at 2600 r.p.m. (1459 g) at 4 °C and stored at -80 °C until batch analysis. High-sensitivity CRP concentrations using an immunoturbidimetric assay were determined at the Clinical and Epidemiologic Research Laboratory, Department of Laboratory Medicine at Children's Hospital in Boston. This assay has a sensitivity of 0.03 mg l^{-1} . The day-to-day variability of the assay at concentrations of 0.91, 3.07 and 13.38 mg l^{-1} are 2.81, 1.61 and 1.1%, respectively.

Statistical analysis

We excluded persons without a detectable SCI level (n=3), history of stroke (n=2), incomplete data collection (n=6), inability to obtain blood (n=6), incomplete data on body composition (n=4) or without CRP results (n=1), leaving a sample size of 338 participants. There were 26 subjects who participated in our previous study (2004–2005)²⁵ who were retested. Natural log-transformation of CRP was used to meet modeling assumptions. General linear models (PROC GLM, SAS version 9.4) were used to assess determinants of natural log CRP. A Tukey adjustment was used for multiple comparisons. Trends across percentage-fat and BMI quartiles were assessed using the median values, and trends for mobility and SCI categories were assessed by assigning ordinal numbers. Variables significant in univariable models at the 0.10 level or less were included in multivariate models. We *a priori* assessed characteristics associated with infection (i.e., ulcer history) and considered effects of comorbid diseases as potential confounders.

RESULTS

Participant characteristics

Participant characteristics are presented in Table 1 overall and by primary mobility mode. The mean ± standard deviation age and injury duration were 54.1 ± 14.4 years and 17.3 ± 13.3 years, respectively (Table 1). The majority of participants were male (82%) and white (86%). When screened by a questionnaire at the time of testing, a mild cold or other respiratory illness was reported by 26 persons (7.7%) in the past week. A history of skin ulcers, urinary tract infections and catheter use was more common among motorized and hand-propelled wheelchair users. There were 83 people (25%) with CRP levels <1 mg l^{-1} (defined as low cardiovascular risk),¹¹ 105 (31%) with CRP levels of 1–3 mg l^{-1} and 150 (44%) people with CRP levels of

Table 2 Univariable associations with ln CRP (mg l⁻¹; N= 338)

| Clinical factors, continuous covariates | e ^(β) | e ^(95% CI) | P-value |
|---|----------------------------|-----------------------|---------------------|
| Age (yrs) | 1.00 | 0.99, 1.01 | 0.960 |
| Injury duration (yrs) | 1.00 | 0.99, 1.01 | 0.689 |
| Pack Years | 1.00 | 1.00, 1.01 | 0.165 |
| Clinical factors, categorical covariates | e ^(ln mean CRP) | e ^(95% CI) | P |
| Sex | | | 0.374 |
| Female | 2.27 | 1.59, 3.25 | |
| Male | 2.71 | 2.30, 3.20 | |
| Race | | | 0.038 |
| White | 2.47 | 2.10, 2.90 | |
| Non-white | 3.92 | 2.61, 5.89 | |
| SCI Classification | | | P-trend |
| Motor complete cervical and AIS C | 4.02 | 2.97, 5.43 | <0.001 |
| Motor complete high thoracic ^a and AIS C | 3.57 | 2.40, 5.31 | |
| Other motor complete and AIS C | 3.00 | 2.16, 4.16 | |
| All AIS D | 1.77 | 1.41, 2.21 | |
| Mobility mode | | | P-trend |
| Motorized wheelchair | 5.53 | 3.98, 7.68 | <0.001 |
| Hand-propelled wheelchair | 2.79 | 2.25, 3.45 | |
| Walk with aid | 2.22 | 1.56, 3.14 | |
| Walk without assistance | 1.31 | 0.95, 1.81 | |
| Skin Ulcers | | | |
| Now | 2.40 | 2.05, 2.81 | <0.001 |
| None now | 5.38 | 3.45, 8.37 | |
| In the past year | 4.03 | 2.99, 5.41 | 0.001 |
| None in the past year | 2.28 | 1.92, 2.71 | |
| In the past 3 years | 3.85 | 2.96, 5.01 | 0.001 |
| None in the past 3 years | 2.28 | 1.84, 2.63 | |
| Uses urinary catheter | | | |
| Yes | 3.67 | 3.02, 4.45 | <0.001 ^b |
| Periodic catheterization | 3.36 | 2.60, 4.34 | |
| Chronic catheter | 4.55 | 3.14, 6.59 | |
| Condom catheter | 3.48 | 2.14, 5.67 | |
| No | 1.70 | 3.02, 4.45 | |
| Urinary tract infections (UTIs) | | | |
| Now | 4.94 | 2.85, 8.56 | 0.020 |
| None now | 2.50 | 2.14, 2.92 | |
| In the past year | 3.61 | 2.86, 4.56 | <0.001 |
| None in the past year | 2.12 | 1.75, 2.57 | |
| In the past 3 years | 2.93 | 2.41, 3.56 | 0.094 |
| None in the past 3 years | 2.26 | 1.78, 2.85 | |
| Current statin use | | | 0.166 |
| Yes | 2.25 | 1.73, 2.94 | |
| No | 2.83 | 2.36, 3.39 | |
| Regular dental care | | | 0.894 |
| Yes | 2.61 | 2.09, 3.39 | |
| No | 2.66 | 2.15, 3.17 | |
| Chest illness in the past year | | | 0.807 |
| Yes | 2.50 | 1.62, 3.85 | |
| No | 2.65 | 2.25, 3.11 | |

Table 2 (Continued)

| Clinical factors, continuous covariates | e ^(β) | e ^(95% CI) | P-value |
|--|------------------|-----------------------|---------|
| Chest illness in the past 3 years (n = 337) | | | 0.184 |
| Yes | 3.14 | 2.31, 4.26 | |
| No | 2.47 | 2.08, 2.94 | |
| Respiratory illness in the past week (n = 336) | | | 0.096 |
| Yes | 4.10 | 2.28, 5.01 | |
| No | 2.54 | 2.14, 2.97 | |
| Heart disease | | | 0.325 |
| Yes | 3.24 | 2.08, 5.05 | |
| No | 2.56 | 2.18, 3.00 | |
| COPD | | | 0.351 |
| Yes | 2.12 | 1.32, 3.41 | |
| No | 2.69 | 2.30, 3.16 | |
| Asthma | | | 0.958 |
| Yes | 2.60 | 1.72, 3.93 | |
| No | 2.63 | 2.24, 3.10 | |
| Doctor-diagnosed COPD or asthma | | | 0.417 |
| Yes | 2.33 | 1.68, 3.24 | |
| No | 2.71 | 2.29, 3.22 | |
| Diabetes | | | 0.518 |
| Yes | 2.96 | 2.00, 4.38 | |
| No | 2.58 | 2.19, 3.03 | |
| Hypertension | | | 0.378 |
| Yes | 2.87 | 2.24, 3.69 | |
| No | 2.50 | 2.07, 3.02 | |
| Smoking status | | | 0.751 |
| Current | 2.95 | 2.06, 4.24 | |
| Former | 2.63 | 2.08, 3.33 | |
| Never | 2.50 | 1.97, 3.17 | |

Abbreviation: COPD, chronic obstructive pulmonary disease.

^a High thoracic = T1–T6.

^b Catheter/no catheter.

> 3 mg l⁻¹. There were 54 (16%) people with very high CRP levels (> 10 mg l⁻¹). The distribution of natural log CRP was normally distributed (Shapiro–Wilks test $W=0.996$, $P=0.640$), and there was no evidence of outliers.

Univariable associations

In univariable models, age, sex, injury duration, smoking status and pack years of smoking, sex, statin use, dental care and comorbidities were not associated with CRP (Table 2). Both mobility mode and level and completeness of SCI were statistically significantly associated with CRP, with the highest CRP levels observed among motorized wheelchair users and among cervical motor complete and AIS C SCI with a significant linear trend across mobility and SCI level and completeness categories (Table 2). Persons who reported a current skin ulcer or a UTI or reported either in the past one and three years had higher CRP levels compared to persons without these conditions. Persons who used a condom catheter, a chronic indwelling catheter or used periodic catheterization had CRP values that were not statistically significantly different from one another ($P=0.551–0.999$), but

Table 3 Associations between measures of body fat and natural log CRP (mg l⁻¹; N = 338)

| Fat measure | BMI (kg m ⁻²) | | | DXA-Total body % fat | | | DXA-Trunk % fat | | | DXA-Android % fat | | | DXA-Gynoid % fat | | |
|----------------------|----------------------------|-----------------------------|---------|----------------------------|-----------------------------|---------|----------------------------|-----------------------------|---------|----------------------------|-----------------------------|---------|----------------------------|-----------------------------|---------|
| | e ^(ln mean CRP) | e ^(95% CI × IQR) | P-value | e ^(ln mean CRP) | e ^(95% CI × IQR) | P-value | e ^(ln mean CRP) | e ^(95% CI × IQR) | P-value | e ^(ln mean CRP) | e ^(95% CI × IQR) | P-value | e ^(ln mean CRP) | e ^(95% CI × IQR) | P-value |
| Continuous | 1.80 | 1.48, 2.19 | <0.001 | 2.28 | 1.90, 2.73 | <0.001 | 2.16 | 1.82, 2.57 | <0.001 | 2.15 | 1.78, 2.59 | <0.001 | 1.93 | 1.58, 2.36 | <0.001 |
| Quartiles | e ^(ln mean CRP) | e ^(95% CI) | P-trend | e ^(ln mean CRP) | e ^(95% CI) | P-trend | e ^(ln mean CRP) | e ^(95% CI) | P-trend | e ^(ln mean CRP) | e ^(95% CI) | P-trend | e ^(ln mean CRP) | e ^(95% CI) | P-trend |
| Quartile 1 (lowest) | 1.56 | 1.16, 2.09 | <0.001 | 1.12 | 0.85, 1.46 | <0.001 | 1.12 | 0.86, 1.46 | <0.001 | 1.23 | 0.94, 1.62 | <0.001 | 1.32 | 1.00, 1.75 | <0.001 |
| Quartile 2 | 2.11 | 1.58, 2.81 | | 2.15 | 1.63, 2.83 | | 2.15 | 1.65, 2.81 | | 1.92 | 1.46, 2.53 | | 2.29 | 1.70, 3.10 | |
| Quartile 3 | 3.39 | 2.53, 4.55 | | 3.58 | 2.73, 4.71 | | 3.27 | 2.49, 4.29 | | 3.48 | 2.64, 4.60 | | 3.97 | 2.99, 5.27 | |
| Quartile 4 (highest) | 4.33 | 3.24, 5.79 | | 5.74 | 4.36, 7.56 | | 6.56 | 4.98, 8.64 | | 5.82 | 4.43, 7.66 | | 3.93 | 2.97, 5.21 | |
| Quartile 1 | <22.8 | | | ≤31 | | | ≤33 | | | ≤35 | | | ≤33 | | |
| Quartile 2 | 22.8 ≤ x < 27.0 | | | 31 < x ≤ 37 | | | 34.3 < x ≤ 41 | | | 35 < x ≤ 45 | | | 33 < x ≤ 41 | | |
| Quartile 3 | 27.0 ≤ x < 31.2 | | | 37 < x ≤ 43 | | | 41 < x ≤ 47 | | | 45 < x ≤ 52 | | | 41 < x ≤ 47 | | |
| Quartile 4 | ≥31.2 | | | >43 | | | >47 | | | >52 | | | >47 | | |

Abbreviations: CI, confidence interval; DXA, dual X-ray absorptiometry; IQR, interquartile range.

each was statistically significantly different from participants who did not use a catheter. Therefore, catheter use was considered as a dichotomous variable. Catheter use was strongly associated with report of a current UTI, as 21 out of the 25 persons with a current UTI used a catheter. Persons who reported a respiratory illness (4.10; 95% CI: 2.28, 5.01 mg l⁻¹) in the past week had greater CRP values compared to persons without an illness (2.54; 95%CI: 2.14, 2.97 mg l⁻¹, P=0.096). Participants who were self-identified as being white had lower CRP values compared to non-white participants (P=0.038). Each measure of adiposity was also statistically significantly positively associated with CRP, with a significant trend across quartiles (Table 3).

Multivariable associations

Due to the high level of collinearity between the DXA-derived measures of adiposity (Pearson r=0.705–0.979, P<0.0001) and a significant correlation between these measures with BMI (r=0.393–0.689, P<0.0001), we created five multivariable models including each adiposity measure separately with other predictors (Table 4). Each adiposity measure (including BMI) was statistically significantly associated with CRP levels in multivariate models (P<0.001). There was a significant positive linear trend across adiposity measure quartiles (not shown), so the continuous measures were used in the final models. Urinary catheter use also remained statistically significantly associated with CRP (P=0.002–0.013), with a better model fit than either current UTI or UTI in the previous year. Participants with a respiratory illness in the week before testing (usually a mild cold) had significantly greater CRP levels (P=0.005–0.015), as did those who were identified as non-white (P=0.001–0.041). In each model (Table 4), participants who reported a current ulcer had a higher CRP compared to persons without an ulcer that was not statistically significant (P=0.096–0.173). Associations with an ulcer reported in the past year (P=0.254–0.450) were weaker and not significant.

In four multivariable models (Table 4), there was a significant linear trend across mobility categories with CRP (P<0.001–0.018), and a suggestive relationship in an additional model (P=0.069). When included in these models, SCI level and completeness was not a statistically significant predictor of CRP (P=0.554–0.974).

Effect of chronic disease

In order to account for effects of comorbid diseases on CRP as potential confounders, we individually added heart disease, diabetes, hypertension, COPD, asthma and any obstructive lung disease (asthma or COPD) into the final multivariable models. The effects of measures of adiposity, urinary catheter, respiratory illness in the past week, current skin ulcer, race and mobility mode did not meaningfully change (data not shown). Heart disease was significantly associated with a greater CRP (P=0.021–0.039) in all models as was hypertension in the model that included gynoid fat (P=0.015). Hypertension in other models (P=0.100–0.157), diabetes (P=0.198–0.770), COPD (P=0.786–0.976), asthma (P=0.163–0.372) and any obstructive lung disease (asthma or COPD) (P=0.305–0.440) were not significantly associated with CRP.

DISCUSSION

In this cross-sectional study in a cohort of individuals with chronic SCI, we found that measures of adiposity (BMI, percentage total body fat, percentage trunk fat, percentage android fat and percentage gynoid fat), mobility mode, catheter use, race and respiratory illness in the past week were all independently associated with circulating levels of

Table 4 Multivariable associations with natural log CRP (mg l⁻¹; N = 336)

| | BMI (kg m ⁻²) | | | DXA-Total body % fat | | | DXA-Trunk % fat | | | DXA-Android % fat | | | DXA-Gynoid % fat | | |
|---|----------------------------|-----------------------|---------|----------------------------|-----------------------|-----------------|----------------------------|-----------------------|-----------------|----------------------------|-----------------------|-----------------|----------------------------|-----------------------|-----------------|
| | e ^(ln mean CRP) | e ^(95% CI) | P-value | e ^(ln mean CRP) | e ^(95% CI) | P-value | e ^(ln mean CRP) | e ^(95% CI) | P-value | e ^(ln mean CRP) | e ^(95% CI) | P-value | e ^(ln mean CRP) | e ^(95% CI) | P-value |
| Continuous fat measure | 1.84 | 1.53, 2.21 | <0.001 | 2.06 | 1.71, 2.47 | <0.001 | 1.99 | 1.68, 2.35 | <0.001 | 1.98 | 1.66, 2.37 | <0.001 | 1.66 | 1.35, 2.05 | <0.001 |
| <i>Other clinical factors</i> | | | | | | | | | | | | | | | |
| Ulcer(s) now | 5.35 | 3.33, 8.59 | 0.096 | 5.64 | 3.55, 8.94 | 0.167 | 5.51 | 3.49, 8.72 | 0.154 | 5.41 | 3.41, 8.60 | 0.173 | 5.98 | 3.68, 9.71 | 0.130 |
| No ulcer(s) now | 3.70 | 2.76, 4.96 | | 4.18 | 3.14, 5.56 | | 4.06 | 3.06, 5.39 | | 4.02 | 3.02, 5.36 | | 4.23 | 3.13, 5.72 | |
| Urinary catheter | 5.62 | 3.86, 8.18 | 0.009 | 6.30 | 4.37, 9.08 | 0.003 | 6.18 | 4.30, 8.88 | 0.002 | 6.07 | 4.21, 8.75 | 0.003 | 6.33 | 4.31, 9.29 | 0.013 |
| No urinary catheter | 3.52 | 2.43, 5.09 | | 3.73 | 2.61, 5.35 | | 3.62 | 2.53, 5.18 | | 3.59 | 2.50, 5.15 | | 4.00 | 2.74, 5.84 | |
| Respiratory illness in the past 1 week | 6.13 | 3.63, 10.35 | 0.012 | 6.69 | 4.02, 11.14 | 0.010 | 6.40 | 3.86, 10.62 | 0.015 | 6.39 | 3.83, 10.66 | 0.012 | 7.26 | 4.25, 12.42 | 0.005 |
| No respiratory illness in the past 1 week | 3.22 | 2.49, 4.17 | | 3.52 | 2.74, 4.53 | | 3.50 | 2.73, 4.49 | | 3.41 | 2.65, 4.38 | | 3.48 | 2.67, 4.54 | |
| White | 3.63 | 2.64, 4.99 | 0.041 | 3.56 | 2.61, 4.85 | 0.001 | 3.51 | 2.58, 4.78 | 0.002 | 3.55 | 2.60, 4.85 | 0.005 | 3.87 | 2.79, 5.35 | 0.010 |
| Non-white | 5.45 | 3.52, 8.43 | | 6.62 | 4.33, 10.12 | | 6.37 | 4.18, 9.71 | | 6.12 | 4.00, 9.37 | | 6.55 | 4.19, 10.23 | |
| Mobility mode | | | | | | | | | | | | | | | |
| Motorized wheelchair | 8.36 | 5.37, 12.99 | <0.001 | 6.83 | 4.41, 10.57 | p-trend = 0.069 | 7.31 | 4.75, 11.24 | p-trend = 0.013 | 7.74 | 5.01, 11.93 | p-trend = 0.003 | 7.80 | 4.94, 12.31 | p-trend = 0.018 |
| Hand propelled wheelchair | 4.61 | 3.20, 6.63 | | 4.31 | 3.02, 6.15 | | 4.22 | 2.97, 6.01 | | 4.22 | 2.95, 6.03 | | 4.33 | 2.98, 6.29 | |
| Walk with aid | 3.66 | 2.32, 5.75 | | 4.73 | 3.06, 7.33 | | 4.44 | 2.88, 6.84 | | 4.27 | 2.76, 6.62 | | 5.06 | 3.20, 8.02 | |
| Walk without assistance | 2.78 | 1.77, 4.35 | | 3.98 | 2.56, 6.20 | | 3.66 | 2.36, 5.66 | | 3.40 | 2.19, 5.28 | | 3.75 | 2.35, 5.99 | |

CRP. There was a strong linear association found between SCI level and CRP in univariable models ($P < 0.0001$) that was not evident after adjustment for mobility mode. We previously reported similar results in a smaller study ($n = 63$) in our earlier chronic SCI cohort, indicating that these findings are reproducible in the SCI population.²⁵ The effects of clinical factors identified in multivariable models were not affected after adjustment for comorbidities that included heart disease, hypertension, diabetes, COPD and asthma. Although heart disease history was significantly associated with a higher CRP value in multivariate models, it did not confound the relationship between the clinical factors included in the multivariable models and CRP.

Pressure ulcers and UTIs have been previously associated with an elevated CRP level.^{9,10} The participants in this cohort were tested when they were feeling well and were able to sit upright for study-related procedures. This likely explains why relatively few persons reported a current skin ulcer (11.2%) and its weak association with CRP in the multivariate models. Considerably more persons (25.2%) reported a skin ulcer in the past year. Similarly, few persons in our cohort reported a current UTI (7.4%), but many reported having a UTI in the past year (40.2%). Both chronic, intermittent and condom catheter use are known correlates of chronic bacteriuria and pyuria,²⁸ which is most likely responsible for the higher CRP values associated with catheter use.

We directly assessed percent fat in the android, gynoid and trunk regions, as well as total body fat by DXA scan. In SCI, due to a decrease in lean mass and increase in fat mass and in central (truncal) fat,^{6,7,29} BMI may not accurately assess adiposity.³⁰ However, we found similar effects of BMI and other measures of adiposity on CRP levels in multivariate models, most likely attributable to the high degree of correlation between the fat measures.

Our findings support the hypothesis that physiologic changes that occur following SCI attributable to decreased mobility, bladder dysfunction and skin ulcers contribute to CRP and systemic inflammation and, therefore, potentially future risk of cardiovascular disease. Many studies in persons without SCI have found higher levels of CRP to be associated with lower levels of physical activity.^{1-3,31} Evidence that chronic or recurrent infection may be associated with cardiovascular disease comes from positive associations between periodontal disease and carotid intima-media thickness,³² and the timing of a myocardial infarction and a preceding systemic respiratory tract³³ or urinary tract infection³⁴ in persons without chronic SCI.

A considerable strength of this study is the use of a comprehensive standardized approach allowing the consideration of multiple factors potentially associated with CRP in a large chronic SCI cohort. Limitations include reliance on self-report of current ulcer, UTI and of chronic medical conditions. However, we have previously validated the use of self-report of chronic medical conditions in this population.¹⁴ Misclassification would make it more difficult to detect the true associations with CRP.

Our study findings support the importance of studying modifiable factors in chronic SCI that can impact health. A longitudinal study is needed to assess the relationship between factors identified, chronic elevations in CRP and subsequent effects on cardiovascular health. Addressing modifiable factors related to obesity, reduced physical activity and recurrent infection could potentially help in lowering the risk of cardiovascular disease among those with chronic SCI.

CONFLICT OF INTEREST

The authors declare no conflict of interest. Supported by VA Rehabilitation Research and Development Merit Review Grant B6618R and I01 RX000792

from the U.S. Department of Veterans Affairs Rehabilitation Research and Development Service; and NIH Grant R01 AR059270. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.

- 1 Kaspis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. *J Am Coll Cardiol* 2005; **45**: 1563-1569.
- 2 Nicklas BJ, You T, Pahor M. Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training. *CMAJ* 2005; **172**: 1199-1209.
- 3 Fischer CP, Berntsen A, Perstrup LB, Eskildsen P, Pedersen BK. Plasma levels of interleukin-6 and C-reactive protein are associated with physical inactivity independent of obesity. *Scand J Med Sci Sports* 2007; **17**: 580-587.
- 4 Penninx BW, Kritchevsky SB, Newman AB, Nicklas BJ, Simonsick E, Rubin S *et al*. Inflammatory markers and incident mobility limitation in the elderly. *J Am Geriatr Soc* 2004; **52**: 1105-1113.
- 5 Ferrucci L, Harris TB, Guralnik JM, Tracy RP, Corti MC, Cohen HJ *et al*. Serum IL-6 level and the development of disability in older persons. *J Am Geriatr Soc* 1999; **47**: 639-646.
- 6 Spungen AM, Adkins RH, Stewart CA, Wang J, Pierson RN Jr, Waters RL *et al*. Factors influencing body composition in persons with spinal cord injury: a cross-sectional study. *J Appl Physiol* 2003; **95**: 2398-2407.
- 7 Maggioni M, Bertoli S, Margonato V, Merati G, Veicsteinas A, Testolin G. Body composition assessment in spinal cord injury subjects. *Acta Diabetol* 2003; **40** (Suppl 1): S183-S186.
- 8 Edwards LA, Bugaresti JM, Buchholz AC. Visceral adipose tissue and the ratio of visceral to subcutaneous adipose tissue are greater in adults with than in those without spinal cord injury, despite matching waist circumferences. *Am J Clin Nutrition* 2008; **87**: 600-607.
- 9 Segal JL, Gonzales E, Yousefi S, Jamshidipour L, Brunneemann SR. Circulating levels of IL-2R, ICAM-1, and IL-6 in spinal cord injuries. *Arch Phys Med Rehabil* 1997; **78**: 44-47.
- 10 Frost F, Roach MJ, Kushner I, Schreiber P. Inflammatory C-reactive protein and cytokine levels in asymptomatic people with chronic spinal cord injury. *Arch Phys Med Rehabil* 2005; **86**: 312-317.
- 11 Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M *et al*. Markers of inflammation and cardiovascular disease. *Circulation* 2003; **107**: 499-511.
- 12 LaVela SL, Evans CT, Prohaska TR, Miskevics S, Ganesh SP, Weaver FM. Males aging with a spinal cord injury: prevalence of cardiovascular and metabolic conditions. *Arch Phys Med Rehabil* 2012; **93**: 90-95.
- 13 DeVivo MJ, Krause JS, Lammertse DP. Recent trends in mortality and causes of death among persons with spinal cord injury. *Arch Phys Med Rehabil* 1999; **80**: 1411-1419.
- 14 Garshick E, Kelley A, Cohen SA, Garrison A, Tun CG, Gagnon D *et al*. A prospective assessment of mortality in chronic spinal cord injury. *Spinal Cord* 2005; **43**: 408-416.
- 15 Osterthun R, Post MWM, van Asbeck FWA, van Leeuwen CMC, van Koppenhagen CF. Causes of death following spinal cord injury during inpatient rehabilitation and the first five years after discharge. *Spinal Cord* 2014; **52**: 483-488.
- 16 Rabadi MH, Mayanna SK, Vincent AS. Predictors of mortality in veterans with traumatic spinal cord injury. *Spinal Cord* 2013; **51**: 784-788.
- 17 Sabre L, Rekan T, Asser T, Korv J. Mortality and causes of death after traumatic spinal cord injury in Estonia. *J Spinal Cord Med* 2013; **36**: 687-694.
- 18 Whiteneck GG, Charlifue SW, Frankel HL, Fraser MH, Gardner BP, Gerhart KA *et al*. Mortality, morbidity, and psychosocial outcomes of persons spinal cord injured more than 20 years ago. *Paraplegia* 1992; **30**: 617-630.
- 19 Nash MS, Tractenberg RE, Mendez AJ, David M, Ljungberg IH, Tinsley EA *et al*. Cardiometabolic syndrome in people with spinal cord injury/disease: guideline derived and nonguideline risk components in a pooled sample. *Arch Phys Med Rehabil* 2016; **97**: 1696-1705.
- 20 Wang TD, Wang YH, Huang TS, Su TC, Pan SL, Chen SY. Circulating levels of markers of inflammation and endothelial activation are increased in men with chronic spinal cord injury. *J Formosa Med Assoc*. 2007; **106**: 919-928.
- 21 Huang CC, Liu CW, Weng MC, Chen TW, Huang MH. Association of C-reactive protein and insulin resistance in patients with chronic spinal cord injury. *J Rehabil Med* 2008; **40**: 819-822.
- 22 Liang H, Mojtahedi MC, Chen D, Braunschweig CL. Elevated C-reactive protein associated with decreased high-density lipoprotein cholesterol in men with spinal cord injury. *Arch Phys Med Rehabil* 2008; **89**: 36-41.
- 23 Gibson AE, Buchholz AC, Ginis KM. C-Reactive protein in adults with chronic spinal cord injury: increased chronic inflammation in tetraplegia vs paraplegia. *Spinal Cord* 2008; **46**: 616-621.
- 24 Laughton GE, Buchholz AC, Ginis KM, Goy RE. Lowering body mass index cutoffs better identifies obese persons with spinal cord injury. *Spinal cord* 2009; **47**: 757-762.
- 25 Morse LR, Stolzmann K, Nguyen HP, Jain NB, Zayac C, Gagnon DR *et al*. Association between mobility mode and C-reactive protein levels in men with chronic spinal cord injury. *Arch Phys Med Rehabil* 2008; **89**: 726-731.
- 26 Kirshblum SC, Waring W, Biering-Sorensen F, Burns SP, Johansen M, Schmidt-Read M *et al*. Reference for the 2011 revision of the International Standards for Neurological Classifications of Spinal Cord Injury. *J Spinal Cord Med* 2011; **34**: 547-554.

- 27 Ferris BG. Epidemiology Standardization Project (American Thoracic Society). *Am Rev Respir Dis* 1978; **188**: 1–120.
- 28 Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. *Clinical Infectious Diseases* 2005; **40**: 643–654.
- 29 Jones LM, Legge M, Goulding A. Healthy body mass index values often underestimate body fat in men with spinal cord injury. *Arch Phys Med Rehabil* 2003; **84**: 1068–1071.
- 30 Cirnigliaro CM, LaFontaine MF, Dengel DR, Bosch TA, Emmons RR, Kirshblum SC *et al*. Visceral adiposity in persons with chronic spinal cord injury determined by dual energy x-ray absorptiometry. *Obesity* 2015; **23**: 1811–1817.
- 31 Mora S, Lee IM, Buring JE, Ridker PM. 2006. Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. *JAMA* 2006; **295**: 1412–1419.
- 32 Aarabi G, Eberhard J, Reissmann D, Heydecke G, Seedorf U. Interaction between periodontal disease and atherosclerotic vascular disease—fact or fiction? *Atherosclerosis* 2015; **241**: 555–560.
- 33 Barnes M, Heywood AE, Mahimbo A, Rahman B, Newall AT, Macintyre CR. Acute myocardial infarction and influenza: a meta-analysis of case-control studies. 2015; **101**: 1738–1747.
- 34 Sims JB, de Lemos JA, Maewal P, Warner JJ, Peterson GE, McGuire DK. Urinary tract infection in patients with acute coronary syndrome: a potential systemic inflammatory connection. *Am Heart J* 2005; **149**: 1062–1065.